Differentials

Idiopathic thrombocytopenic purpura (ITP)

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Rash of ITP may also have petechiae. Arthralgias and abdominal pain are uncommon.

INVESTIGATIONS

Platelet level is low in ITP, but normal in IgAV.

Hypersensitivity vasculitis

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Usually no renal involvement.

INVESTIGATIONS

Skin biopsy may show leukocytoclastic vasculitis, but no IgA deposition.

Rheumatic fever

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

May have similar clinical features to IgAV; however, the rash in rheumatic fever is erythema marginatum, and not palpable purpura.

INVESTIGATIONS

Predominance of deposition of IgA on biopsy characterises IgAV. Increased anti-streptolysin-O antibody titres have been reported in both rheumatic fever and IgAV, therefore making them difficult to distinguish.

Meningococcal septicaemia

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

May have similar clinical features; rash may also have petechiae.

The child is usually very unwell with meningococcal septicemia.

INVESTIGATIONS

Abnormal coagulation studies and low platelet counts are seen in septicaemia. Positive septic (infection) screen is seen in meningococcal septicaemia. These studies are normal in IgAV.

Haemolytic uraemic syndrome (HUS)

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

May have similar clinical features; rash may also have petechiae. Diarrhoea is common in HUS.

INVESTIGATIONS

Haemolytic anaemia, with elevated reticulocyte counts and low haptoglobin levels, and low platelets are seen in HUS. Stool studies may be helpful in HUS; these studies are normal in IgAV and abnormal in HUS.

IgA nephropathy

SIGNS / SYMPTOMS
INVESTIGATIONS
SIGNS / SYMPTOMS

Rash, abdominal pain, and arthritis are generally not present. Patients are usually aged between 20 to 40 years.

INVESTIGATIONS

Renal biopsy shows similar findings with IgA nephropathy and IgAV. However, patients with IgA nephropathy do not have the other clinical manifestations of IgAV.

Use of this content is subject to our disclaimer